ABG Sundal Collier acted as joint bookrunner in the SEK 301m directed share issue in Q-linea

On Thursday June 10, 2021, Q-linea announced the successful completion of a directed share issue of 2.2 million shares at a price of SEK 137 per share, raising gross proceeds of SEK 301m. This marks the second successful directed share issue in Q-linea during the last two years where ABG Sundal Collier acted as joint bookrunner. The directed share issue was multiple times oversubscribed and attracted strong interest from Swedish and international institutional investors. The price was determined in an accelerated book building process and corresponded to a discount of approximately 5.8 percent in relation to the closing price on Nasdaq Stockholm on June 10, 2021.
Q-linea intends to use the net proceeds from the directed share issue for funding of the final stages of the commercial launch of ASTar® together with its Global sales partner; including ramp-up and increased preparedness to meet higher than initially expected sales volumes, as its Global sales partner increases internal application and sales personnel numbers for their joint conceptual launch; acceleration of development of ASTar® additional assays, including urine and isolates, as well as acceleration of development of the portable blood culturing technology product, preparing for the start of clinical studies in 2022; enhancement of the company’s financial flexibility to pursue additional commercialization activities and geographical expansion; and general corporate purposes.